 |
Association
of British Clinical Diabetologists (ABCD) and Diabetes-UK survey
of specialist diabetes services in the UK, 2006. 1. The consultant
physician perspective |
| |
All 592 UK consultant diabetologists were invited
to participate in an on-line survey (Diabetic Medicine) |
| |
|
|
Diabetes
Online Health Guide Released on NHS Choices |
| |
The guide takes patients through each stage,
from before diagnosis, through to how to live and self-manage the
condition (NHS Choices, UK) |
| |
|
|
New
wireless diabetes management system for UK and Ireland |
| |
Medtronic, Inc. and Bayer Diabetes Care, a division
of Bayer HealthCare and a member of the Bayer Group, today announced
the availability in the UK and Ireland of the Contour® Link blood glucose meter (Diabetes, UK) |
| |
|
|
Diabetic
neuropathy: Mechanisms to management. |
| |
This review covers the pathology, epidemiology,
biochemical pathways, and prevention of diabetic neuropathy, as
well as discusses current symptomatic and causal therapies and
novel approaches to identify therapeutic targets (PubMed, USA) |
| |
|
|
Notification
of random hyperglycaemia to general practitioners by an emergency
medicine team: impact of a simple intervention plan |
| |
EM staff education, together with an automated
laboratory message, significantly improved the rate and quality
of notification of elevated RVPG levels to GPs (Diabetic Medicine) |
| |
|
|
Rediscover
diabetes online with the launch of two new websites |
| |
The websites www.diabetesaustralia.com.au and www.ndss.com.au were
redeveloped after extensive research on the availability of diabetes
information online (AHHA, Australia) |
| |
|
|
Weekly
basal-bolus adjustments may reduce HbA1c levels in patients with
type 2 diabetes |
| |
The efficacy of a simple algorithm and an insulin-to-carbohydrate
ratio to both deliver and adjust prandial insulin may increase
physician and patient willingness to advance to basal-bolus insulin
(Endocrine Today, USA) |
| |
|
|
'Snapshots'
of eyes could serve as early warning of diabetes |
| |
A new vision screening device, already shown
to give an early warning of eye disease, could give doctors and
patients a head start on treating diabetes and its vision complications,
a new study shows (GEN, USA) |
| |
|
|
Post-hoc
analyses of type 2 diabetes patients switch from premixed insulin
regimen to basal insulin plus oral hypoglycemic agents regimen |
| |
Type 2 diabetic patients treated with twice-daily
injection of premixed 30 R insulin with or without OAD (s) can
be effectively and safely switched to basal insulin plus OAD (PubMed,
USA) |
| |
|
|
Diabetes
Experts Share New Research and Discuss Vision for Best Practices |
| |
Diabetes experts throughout the world are meeting
in Washington, DC, to answer these questions: What are the clinical
risks of not treating pre-diabetes? - Can society afford the costs
of treating of not treating the pre-diabetes state? (AACE, USA) |
| |
|
|
Relationships
between insulin secretion after intravenous and oral glucose
administration in subjects with glucose tolerance ranging from
normal to overt diabetes |
| |
Acute insulin release (AIR) in response to intravenous
glucose injection (IVGTT) can be abolished in diabetic subjects
when their response to oral glucose is maintained. To elucidate
this phenomenon, we examined the relationships between fasting
plasma glucose (FPG) and the secretory responses to an IVGTT and
an oral glucose test (Diabetic Medicine) |
| |
|
|
The
relationship between islet alpha cell insulin resistance and
inflammatory pathway activation and its mechanism |
| |
High-fat-diet feeding induces islet alpha cell
insulin resistance and activates the mRNA expression of inflammatory
path molecules in beta cell-deleted rat models and it may relate
with the increased plasma FFA concentration. Pioglitazone intervention
can reverse these effects (PubMed, USA) |
| |
|
|
Pathophysiology
and treatment of patients with type 2 diabetes exhibiting failure
to oral drugs. |
| |
Patients not responding to GLP-1 mimetics or
experiencing significant side effects will be treated with insulin.
Irrespective of the policy used for the drug treatment of type
2 diabetes, exercise and proper diet will remain important for
optimization of metabolic control (PubMed, USA) |
| |
|
|
Spherix
Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S. |
| |
Spherix Incorporated (Nasdaq: SPEX) reported
that the Phase 3 clinical trial of its potential type 2 diabetes
drug, Naturlose(R), will expand outside of the United States (PRN) |
| |
|
